Aim: Evaluate the utility of glutamate dehydrogenase (GLDH) and cardiac troponin 
I as safety biomarkers, and creatine kinase and muscle injury panel as muscle 
health biomarkers in Duchenne muscular dystrophy. Patients & methods: Data were 
collected during a Phase II trial of domagrozumab. Results: GLDH was a more 
specific biomarker for liver injury than alanine aminotransferase. Cardiac 
troponin I elevations were variable and not sustained, limiting its 
applicability as a biomarker. Muscle injury panel biomarkers were no more 
informative than creatine kinase as a muscle health biomarker. Conclusion: 
Results support the use of GLDH as a specific biomarker for liver injury in 
patients with Duchenne muscular dystrophy. Clinical trial registration: 
ClinicalTrials.gov, NCT02310763.